中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月8日星期二
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (26): 96-98转102    
  肿瘤医学 本期目录 | 过刊浏览 | 高级检索 |
白蛋白结合型紫杉醇联合贝伐单抗在二线治疗失败晚期卵巢癌患者中的应用效果
付慧英 柯传庆 彭恩兰
联勤保障部队第九〇八医院肿瘤科,江西南昌 330000
Application effect of Albumin-bound Paclitaxel combined with Bevacizumab in patients with advanced ovarian cancer who failed second-line therapy
FU Huiying KE Chuanqing PENG Enlan#br#
Department of Oncology, No.908 Hospital, Joint Logistics Support Force, Jiangxi Province, Nanchang 330000, China
全文: PDF (519 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 
目的 探讨白蛋白结合型紫杉醇联合贝伐单抗在二线治疗失败晚期卵巢癌患者中的应用效果。方法 选取2020年1月至2021年4月联勤保障部队第九〇八医院收治的136 例二线治疗失败晚期卵巢癌患者作为研究对象,按照计算机随机数法分为对照组(68 例)与观察组(68 例)。 对照组采用经白蛋白结合型紫杉醇治疗方法,观察组采用经白蛋白结合型紫杉醇联合贝伐单抗治疗方法。 比较两组的治疗效果,血清癌胚抗原(CEA)、血清糖链抗原125(CA125)水平和不良反应发生情况。 结果 观察组的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组的CEA、CA125 水平均低于对照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 对于二线治疗失败晚期卵巢癌患者,对其实施经白蛋白结合型紫杉醇联合贝伐单抗治疗方式具有较佳效果,可有效改善患者的CEA、CA125 水平,具有较高的安全性,可结合临床实际需求展开合理推广使用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 二线治疗失败晚期卵巢癌经白蛋白结合型紫杉醇贝伐单抗治疗癌胚抗原糖链抗原125临床疗效    
Abstract
Objective To investigate the effect of Albumin-bound Paclitaxel combined with Bevacizumab in patients with advanced ovarian cancer who failed second-line therapy. Methods From January 2020 to April 2021, 136 patients with advanced ovarian cancer who had failed second-line treatment admitted to the No.908 Hospital, Joint Logistics Support Force were selected as the research subjects. According to computer random number method, the patients were divided into control group (68 cases) and observation group (68 cases). The control group were treated with Albuminbound Paclitaxel, and the observation group was treated with Albumin-bound Paclitaxel combined with Bevacizumab.The treatment effect, serum carcinoembryonic antigen (CEA), serum glucose chain antigen 125 (CA125) levels and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was higher than that of control group, and the difference was statistically significant (P<0.05). After treatment, the levels of CEA and CA125 in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion For patients with advanced ovarian cancer who failed the secondline treatment, the treatment with Albumin-bound Paclitaxel combined with Bevacizumab has a good effect, can effectively improve the CEA and CA125 levels of patients, and has high safety and can be reasonable promotion and use should be carried out in combination with actual clinical needs.
Key wordsAdvanced ovarian cancer after failure of second-line therapy    Albumin-bound Paclitaxel    Bevacizumab therapy    Carcinoembryonic antigen    Sugar chain antigen 125    Clinical efficacy
    
基金资助:江西省卫生健康委科技计划项目(SKJP2202196 40)。
引用本文:   
付慧英;柯传庆;彭恩兰. 白蛋白结合型紫杉醇联合贝伐单抗在二线治疗失败晚期卵巢癌患者中的应用效果[J]. 中国当代医药, 2022, 29(26): 96-98转102.
FU Huiying KE Chuanqing PENG Enlan. Application effect of Albumin-bound Paclitaxel combined with Bevacizumab in patients with advanced ovarian cancer who failed second-line therapy. 中国当代医药, 2022, 29(26): 96-98转102.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I26/96
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载